Auriga

Auriga is out with its report today on Marvell Technology Group (NASDAQ: MRVL), lowering its PT from $18 to $17. In its report, Auriga writes, "We maintain our Buy Rating, but reduce our price target to $17 from $18 for Marvell as we reduce our estimates to account for the impact of Thailand flood...

Auriga has lowered the price target on Marvell Technology Gorup (NASDAQ: MRVL) from $18 to $17 and maintains its Buy rating.

Auriga has published a research report on Juniper Networks (NSYE: JNPR) after the company's 4Q guidance missed expectations. In the report, Auriga writes, "[A] strong 1.2x Book-to-Bill and management commentary about service provider router orders likely being delayed to 1Q12 keeps us optimistic...

Auriga is out with its report today on First Solar (NASDAQ: FSLR), lowering its PT from $120 to $113. In its report, Auriga writes, "To reflect First Solar's operational excellence, offset partially by heightened political/economic concerns, we value the stock at the mid-point of the valuation...

Auriga has lowered the price target on First Solar (NASDAQ: FSLR) from $120 to $113 and maintains its Buy rating.

Auriga has raised the price target on Juniper Networks (NYSE: JNPR) from $24 to $26 and maintains its Buy rating.

Auriga has upgraded Xilinx (NASDAQ: XLNX) from Hold to Buy and has raised the price target from $34 to $36.

According to Auriga, DepoMed (NASDAQ: DEPO) price target is reduced to $7. Auriga said that the company announced negative Serada Phase III results for menopausal hot flashes yesterday. “With $3 per share in cash, we believe the fair valuation based on Glumetza and Gralise alone is $7.” DepoMed...

Auriga has lowered the price target on DepoMed (NASDAQ: DEPO) from $10 to $7 and maintains its Buy rating.

Auriga is out with a research report on Health Management Associates (NYSE: HMA) and it has a Buy rating and a $13 price target on shares. In a note to clients, Auriga writes, "We are slightly increasing our 3Q11 revenue driven mainly by the mix shift of lower volume and higher price vs. our...

Auriga is out with a research report on Universal Health Services, Inc. (NYSE: UHS) and it has a Buy rating and a $45 price target on shares. In a note to clients, Auriga writes, "We are keeping our 3Q11 revenue and earnings the same for 3Q11, 2011 and 2012. We continue to believe that UHS is well...

Auriga is out with a research report on HCA Holdings, Inc. (NYSE: HCA) and it has a Buy rating and a $28 price target on shares. In a note to clients, Auriga writes, "We are slightly lowering our 3Q11 revenue and EPS estimates to adjust for lower volume growth in September in HCA markets, and...

A report from Auriga reiterates its Buy rating and $10 price target on DepoMed (NASDAQ: DEPO). In the report, Auriga writes, “[W]e believe the announcement of Glumetza launch is likely to be during the week of October 10. While the announcement of commercial introduction of Gralise is important...

According to Auriga, Quality Systems (NASDAQ: QSII) price target is raised to $88. Auriga said that it is reiterating its HOLD rating on Quality Systems (QSII) following recent channel checks in the ambulatory and inpatient markets, while increasing estimates slightly for FY12 and FY13 (still...

Auriga is out with its report today on Illumina (NASDAQ: ILMN), lowering its PT to $47. In its report, Auriga writes, "While we had been anticipating some weakness in the quarter given the funding environment, the magnitude of the miss surprised us. Given the preannouncement and suspension of...